{"transactions":[{"id":3885573,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165548,"kind":"person","name":"SANDAGE BOBBY W. JR., PHD.","position":1,"cik":"0001046352","reported_name":"SANDAGE BOBBY W. JR., PHD.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-22T20:16:23.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":258171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per shares (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Amended and Restated Mateon Therapeutics, Inc. 2015  Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 20, 2019, subject to Dr. Sandage's continued service on the Board of Directors as of such date."}],"balance_after":258171,"derivative":{"exercise_price":0.22,"expiration_date":"2024-06-20","underlying":"Common Stock","underlying_shares":258171},"source":{"system":"sec-edgar","filing":"0001209191-18-039183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919118039183/doc4.xml","form_type":"4"}},{"id":4286213,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165548,"kind":"person","name":"SANDAGE BOBBY W. JR., PHD.","position":1,"cik":"0001046352","reported_name":"SANDAGE BOBBY W. JR., PHD.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-13T00:30:56.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":121483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"Stock Options\"), in connection with his service as a member of the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in full on June 9, 2018, subject to Dr. Sandage's continued service on the Board of Directors as of such date."}],"balance_after":121483,"derivative":{"exercise_price":0.51,"expiration_date":"2023-06-09","underlying":"Common Stock","underlying_shares":121483},"source":{"system":"sec-edgar","filing":"0001209191-17-039319","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919117039319/doc4.xml","form_type":"4"}},{"id":4573634,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":165548,"kind":"person","name":"SANDAGE BOBBY W. JR., PHD.","position":1,"cik":"0001046352","reported_name":"SANDAGE BOBBY W PHD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-27T20:28:58.000Z","date":"2016-10-25","kind":"grant","acquired":true,"shares":135612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Dr. Sandage was awarded options to purchase shares of Mateon Therapeutics, Inc. common stock, $0.01 par value per share (the \"Stock Options\"), in connection with his appointment to the Board of Directors pursuant to the Mateon Therapeutics, Inc. 2015 Equity Incentive Plan and the Amended and Restated Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Options will vest in three equal annual installments on the first, second and third anniversary of the date of grant, subject to Dr. Sandage's continued service on the Board of Directors as of such date."}],"balance_after":135612,"derivative":{"exercise_price":0.58,"expiration_date":"2022-10-25","underlying":"Common Stock","underlying_shares":135612},"source":{"system":"sec-edgar","filing":"0001209191-16-147151","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000120919116147151/doc4.xml","form_type":"4"}}]}